Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Adiponectin in the heart and vascular system.

Ding M, Rzucidlo EM, Davey JC, Xie Y, Liu R, Jin Y, Stavola L, Martin KA.

Vitam Horm. 2012;90:289-319. doi: 10.1016/B978-0-12-398313-8.00011-7. Review.

PMID:
23017720
2.

The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS.

Kadowaki T, Yamauchi T, Kubota N.

FEBS Lett. 2008 Jan 9;582(1):74-80. Epub 2007 Dec 3. Review.

3.

Cardiovascular actions of adiponectin: pathophysiologic implications.

Maia-Fernandes T, Roncon-Albuquerque R Jr, Leite-Moreira AF.

Rev Port Cardiol. 2008 Nov;27(11):1431-49. Review. English, Portuguese.

4.

Adiponectin and its role in cardiovascular diseases.

Bełtowski J, Jamroz-Wiśniewska A, Widomska S.

Cardiovasc Hematol Disord Drug Targets. 2008 Mar;8(1):7-46. Review.

PMID:
18336252
5.

Adiponectin and interleukin-6 in inflammation-associated disease.

Li L, Wu LL.

Vitam Horm. 2012;90:375-95. doi: 10.1016/B978-0-12-398313-8.00014-2. Review.

PMID:
23017723
6.

Cardiometabolic effects of adiponectin.

Parker-Duffen JL, Walsh K.

Best Pract Res Clin Endocrinol Metab. 2014 Jan;28(1):81-91. doi: 10.1016/j.beem.2013.09.001. Epub 2013 Sep 13. Review.

7.

Adiponectin and PPARγ: cooperative and interdependent actions of two key regulators of metabolism.

Astapova O, Leff T.

Vitam Horm. 2012;90:143-62. doi: 10.1016/B978-0-12-398313-8.00006-3. Review.

PMID:
23017715
8.

Adiponectin and its correlates of cardiovascular risk in young adults: the Bogalusa Heart Study.

Patel DA, Srinivasan SR, Xu JH, Chen W, Berenson GS.

Metabolism. 2006 Nov;55(11):1551-7.

PMID:
17046560
9.

Adiponectin: from obesity to cardiovascular disease.

Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C.

Obes Rev. 2009 May;10(3):269-79. doi: 10.1111/j.1467-789X.2009.00571.x. Epub 2009 Mar 6. Review.

PMID:
19389061
10.

[Adipokines as novel cardiovascular disease markers. Pathological and clinical considerations].

González-Juanatey JR, Paz FL, Eiras S, Teijeira-Fernández E.

Rev Esp Cardiol. 2009 Jun;62 Suppl 2:9-16. Spanish.

11.
12.
13.

Endocrine and signalling role of adipose tissue: new perspectives on fat.

Trayhurn P.

Acta Physiol Scand. 2005 Aug;184(4):285-93. Review.

PMID:
16026420
14.

[Adipokines: adiponectin, leptin, resistin and coronary heart disease risk].

Kopff B, Jegier A.

Przegl Lek. 2005;62 Suppl 3:69-72. Review. Polish.

PMID:
16521924
15.

Adiponectin: linking the metabolic syndrome to its cardiovascular consequences.

Rabin KR, Kamari Y, Avni I, Grossman E, Sharabi Y.

Expert Rev Cardiovasc Ther. 2005 May;3(3):465-71. Review.

PMID:
15889974
16.

Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease.

Xu A, Vanhoutte PM.

Am J Physiol Heart Circ Physiol. 2012 Mar 15;302(6):H1231-40. doi: 10.1152/ajpheart.00765.2011. Epub 2011 Dec 30. Review.

PMID:
22210749
17.

Adiponectin--a key adipokine in the metabolic syndrome.

Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB.

Diabetes Obes Metab. 2006 May;8(3):264-80. Review.

PMID:
16634986
18.

Adiponectin: an update.

Guerre-Millo M.

Diabetes Metab. 2008 Feb;34(1):12-8. Review.

PMID:
18069030
19.

Adipokines as uremic toxins.

Teta D.

J Ren Nutr. 2012 Jan;22(1):81-5. doi: 10.1053/j.jrn.2011.10.029. Review.

PMID:
22200420
20.

Adipokines and the cardiovascular system: mechanisms mediating health and disease.

Northcott JM, Yeganeh A, Taylor CG, Zahradka P, Wigle JT.

Can J Physiol Pharmacol. 2012 Aug;90(8):1029-59. doi: 10.1139/y2012-053. Epub 2012 May 30. Review.

PMID:
22646022

Supplemental Content

Support Center